The collection represents 17 different areas of clinical medicine and is the world’s largest series of review journals in research, development and clinical medicine. The articles found in the Expert Collection journals present the personal opinions of authors who are all internationally recognized experts in their fields. They provide their view on where research in their specialism is now, where it should go next, and how it should get there.
As well as publishing reviews, all journals welcome and encourage submission of original research articles. Author guidance can be found here. By publishing your original research in an Expert Reviews journal you will benefit from an in-house editorial team with aims of getting back to back to authors within 24 hours.
Expert Opinion on Therapeutic Targets
2020 Impact Factor 6.902
Five-Year Impact Factor 6.060
A MEDLINE-indexed journal covering novel molecular disease targets while providing expert opinion on their scope for future drug development and the impact on drug discovery. Content evaluates molecules, signaling pathways, receptors, and other therapeutic targets.
Expert Opinion on Orphan Drugs
2020 Impact Factor 0.694
Five-Year Impact Factor 0.769
Covering all aspects of research and development on rare diseases and orphan drugs. Topics include pharmacogenomics and screening, prevalence and epidemiology, drug development, clinical trials, regulatory issues, post-marketing safety, and treatment outcomes.
Read for free!
For a limited time, we're offering you free access* to a selection of our key articles.
*When accessed via this page only. Applicable to non open access content only.
|TGF-beta: a master immune regulator||Expert Opinion on Therapeutic Targets||24||5|
|Desmoplastic small round cell tumor (DSRCT): emerging therapeutic targets and future directions for potential therapies||Expert Opinion on Therapeutic Targets||24||4|
|Overexpression of HMGA2 in breast cancer promotes cell proliferation, migration, invasion and stemness||Expert Opinion on Therapeutic Targets||24||3|
|Current state of developing advanced therapies for rare diseases in the European Union||Expert Opinion on Orphan Drugs||8||10|
|Rare cancers, the continued agenda for progress – editor’s special foreword||Expert Opinion on Orphan Drugs||8||9|
|Advances in therapeutic treatment options for ANCA-associated vasculitis||Expert Opinion on Orphan Drugs||8||4|
SHARE THIS PAGE